Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas

Veronica Langenes1, Helena Svensson, Lars Börjesson

  • 1Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Box 435, 405 30, Göteborg, Sweden, veronica.langenes@microbio.gu.se.

Insights

Colon tumors show reduced expression of the D6 decoy receptor, which normally controls immune cell migration. This decrease correlates with increased tumor invasiveness and may impact immunotherapy strategies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Immune cell recruitment to tumors is vital for both tumor growth and anti-tumor responses.
  • Chemokines and their decoy receptors, like D6, regulate immune cell migration.
  • The specific role of D6 in tumor immunity remains largely undefined.

Purpose of the Study:

  • To investigate the expression and function of the D6 decoy receptor in colon tumors.
  • To determine the relationship between D6 expression, tumor characteristics, and the tumor microenvironment.

Main Methods:

  • Real-time PCR to quantify D6 mRNA levels in tumor and adjacent healthy colon tissue.
  • Immunohistochemistry to detect D6 protein expression in tissue samples.
  • Analysis of lymphatic vessel density using Lyve-1 marker.
  • Quantification of CCL22 chemokine levels in tumor tissue.

Main Results:

  • D6 mRNA expression was significantly lower in colon tumors compared to unaffected mucosa.
  • D6 protein was detected in lymphatic endothelium and mononuclear cells, correlating with high mRNA levels.
  • Increased lymphatic vessel density was observed in tumors.
  • CCL22, a D6-sequestered chemokine, was elevated threefold in tumor tissue.
  • Lower D6 expression correlated with increased tumor invasiveness and was reduced in distal colon locations.

Conclusions:

  • Colon tumors downregulate D6 expression, altering chemokine networks to promote tumor survival.
  • This dysregulation of D6 influences the tumor microenvironment and immune cell infiltration.
  • Findings suggest D6 modulation could be a therapeutic target for colon cancer immunotherapy.